PUBLISHER: DelveInsight | PRODUCT CODE: 1159563
PUBLISHER: DelveInsight | PRODUCT CODE: 1159563
DelveInsight's , "Neonatal respiratory distress syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Neonatal respiratory distress syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Neonatal respiratory distress syndrome Understanding
Neonatal respiratory distress syndrome: Overview
Neonatal respiratory distress syndrome, or RDS, is a common cause of respiratory distress in a newborn, presenting within hours after birth, most often immediately after delivery. RDS primarily affects preterm neonates, and infrequently, term infants. The incidence of RDS is inversely proportional to the gestational age of the infant, with more severe disease in the smaller and more premature neonates. While treatment modalities, including antenatal corticosteroids, surfactants, and advanced respiratory care of the neonate, have improved the outcomes for patients affected by RDS, it continues to be a leading cause of morbidity and mortality in the preterm infant. Neonatal respiratory distress syndrome (RDS) occurs from a deficiency of surfactant, due to either inadequate surfactant production, or surfactant inactivation in the context of immature lungs. Prematurity affects both these factors, thereby directly contributing to RDS. Since the definition of neonatal respiratory distress syndrome is imprecise, prompt diagnosis and treatment require an overall assessment of prenatal and delivery history to identify perinatal risk factors, clinical presentation, radiographic findings, and evidence of hypoxemia on blood gas analysis. The goals of optimal management of neonatal respiratory distress syndrome include decreasing incidence and severity using antenatal corticosteroids, followed by optimal management using respiratory support, surfactant therapy, and overall care of the premature infant.
"Neonatal respiratory distress syndrome - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neonatal respiratory distress syndrome pipeline landscape is provided which includes the disease overview and Neonatal respiratory distress syndrome treatment guidelines. The assessment part of the report embraces, in depth Neonatal respiratory distress syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neonatal respiratory distress syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Neonatal respiratory distress syndrome Emerging Drugs Chapters
This segment of the Neonatal respiratory distress syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neonatal respiratory distress syndrome Emerging Drugs
AEROSURF® is drug-device combination that incorporates lucinactant to treat premature infants suffering from respiratory distress syndrome a complication with preterm births due to the infant's lungs lacking endogenous surfactant. AEROSURF® allows for the non-invasive delivery of surfactant in order to avoid the well-known complications associated with invasive administration, intubation and ventilation using its proprietary aerosol delivery system (ADS). Data from Phase 2 trials have demonstrated that AEROSURF has the potential to improve lung function in premature infants with RDS.
AP-002 is a nasally inhaled surfactant based on a combination of Lyomark's Alveofact® (bovine lung surfactant) and Aerogen's next generation "PDAP™" delivery technology. The partners expect AP-002 to set a new standard in the treatment of RDS, since it will enable surfactant administration via the nose and complement current first line therapy with nasal continuous positive airway pressure ventilation (nCPAP). AP-002 is anticipated to reduce the need for sedation, invasive intubation and mechanical ventilation, all features of current surfactant treatment methods associated with adverse side effects and the potential to exacerbate chronic lung disease in preterm infants. According to the company's pipeline, it is in Phase II stage of clinical trial evaluation to treat respiratory distress syndrome (RDS) in premature infants.
Further product details are provided in the report……..
Neonatal respiratory distress syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Neonatal respiratory distress syndrome drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the therapies for Neonatal respiratory distress syndrome. The companies which have their Neonatal respiratory distress syndrome drug candidates in the most advanced stage, i.e. phase II include, Windtree Therapeutics.
DelveInsight's report covers around 3+ products under different phases of clinical development like
Neonatal respiratory distress syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Neonatal respiratory distress syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neonatal respiratory distress syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neonatal respiratory distress syndrome drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Neonatal respiratory distress syndrome: Overview
Pipeline Therapeutics
Therapeutic Assessment
Neonatal respiratory distress syndrome - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AEROSURF: Windtree Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Neonatal respiratory distress syndrome mesenchymal stem cell therapy: Anakuria Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Neonatal respiratory distress syndrome Key Companies
Neonatal respiratory distress syndrome Key Products
Neonatal respiratory distress syndrome- Unmet Needs
Neonatal respiratory distress syndrome- Market Drivers and Barriers
Neonatal respiratory distress syndrome- Future Perspectives and Conclusion
Neonatal respiratory distress syndrome Analyst Views
Neonatal respiratory distress syndrome Key Companies
Appendix